Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A CIBMTR Analysis

For many patients with hematologic malignancies or non-malignant diseases, AlloHCT is the preferred treatment option. Many factors influence whether a patient eligible for transplant will go on to receive a transplant. Patients need to have a disease status that renders them eligible to receive a transplant, have a suitable performance status and organ function, and have an available donor. In addition, many sociodemographic variables such as insurance coverage might impair access to AlloHCT [1].

Source: Biology of Blood and Marrow Transplantation - June 18, 2019 Category: Hematology Authors: Kristjan Paulson, Ruta Brazauskas, Nandita Khera, Naya He, Navneet Majhail, Gorgun Akpek, Mahmoud Aljurf, David Buchbinder, Linda Burns, Sara Beattie, Cesar Freytes, Anne Garcia, James Gajewski, Theresa Hahn, Jennifer Knight, Charles LeMaistre, Hillard La Source Type: research